The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical trial Newton-2 (Protocol #EG-01-1962-03) evaluating a new treatment for certain patients with aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that the blinded assessors at the clinical sites are well versed on the neurologic outcome assessments in this trial. Because the outcome on the GOSE rating scale is the primary endpoint in this study, it is imperative that the assessor has a thorough understanding of the survey methodology, including the ability to perform a thorough assessment of the extent of disability at baseline, prior to the aSAH. We are providing this online training course, assessment tools, and informational updates. Please see the menu for these materials.
Additionally, please feel free to contact us with any questions you may have. Meanwhile, we look forward to working with you!